<DOC>
	<DOCNO>NCT02391805</DOCNO>
	<brief_summary>This randomize , multicenter , partially double-blind , placebo-controlled study design evaluate safety , tolerability , pharmacokinetics , pharmacodynamics , antiviral effect treatment RO6864018 virologically suppress participant chronic HBV infection .</brief_summary>
	<brief_title>A Study Treatment With RO6864018 Virologically Suppressed Participants With Chronic Hepatitis B Virus ( HBV ) Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Adults 18 65 year age Chronic hepatitis B infection Positive test HBsAg 6 month prior randomization HBsAg titer great equal ( &gt; /= ) 250 international unit per milliliter ( IU/mL ) Screening Treatment nucleoside/nucleotide analogue &gt; /= 1 year ongoing entecavir tenofovir treatment randomization least 3 month prior randomization HBV DNA le ( &lt; ) 90 IU/mL least precede 6 month HBeAg positive randomization least 6 month prior randomization Pregnant lactate woman Documented history HBV genotype D History evidence bleed esophageal varix History decompensated liver disease , chronic liver disease HBV infection , evidence metabolic liver disease Positive test hepatitis A , hepatitis C , human immunodeficiency virus ( HIV ) Documented history hepatitis D infection History suspicion hepatocellular carcinoma History immunologically mediate disease History organ transplantation History thyroid disease Significant acute infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>